| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9956549 | International Journal of Cardiology | 2005 | 11 Pages |
Abstract
The cost-effectiveness of pravastatin therapy differs substantially according to the level of cardiac risk. At present, pravastatin therapy is not cost-effective for persons at low cardiac risk.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Shizuko Nagata-Kobayashi, Takuro Shimbo, Kunihiko Matsui, Tsuguya Fukui,